Yoshiaki Ito

Ito Yoshiaki

Appointment(s)
  • Professor, Department of Medicine
  • Senior Principal Investigator, Cancer Science Institute of Singapore, National University of Singapore
Joint Appointment(s)
  • Adjunct Professor, Institute of Molecular and Cell Biology, A*STAR
Academic Qualifications
  • PhD, Tohoku University Graduate School of Medical Sciences, Sendai, Japan
  • MD, Tohoku University, School of Medicine, Sendai, Japan
Research Interest(s)
  • Gastric Cancer
  • RUNX
  • Tumor Suppressor
  • Stem Cells
  • DNA Repair
Recent Publications
  • 1. Kulkarni, M., Tan, T. Z., Sulaiman, N. B. S., Lamar, J. M., Bansal, P., Cui, J., . . . Ito, Y. (2018). RUNX1 and RUNX3 protect against YAP-mediated EMT, stemness and shorter survival outcomes in breast cancer. Oncotarget, 9(18), 14175-14192. doi:10.18632/oncotarget.24419.
  • 2. Krishnan, V., Chong, Y. L., Tan, T. Z., Kulkarni, M., Bin Rahmat, M. B., Tay, L. S., . . . Ito, Y. (2018). TGFβ promotes genomic instability after loss of RUNX3. Cancer Research, 78(1), 88-102. doi:10.1158/0008-5472.CAN-17-1178.
  • 3. Chi, X. -Z., Lee, J. -W., Lee, Y. -S., Park, I. Y., Ito, Y., & Bae, S. -C. (2017). Runx3 plays a critical role in restriction-point and defense against cellular transformation. ONCOGENE, 36(50), 6884-6894. doi:10.1038/onc.2017.290.
  • 4. Selvarajan, V., Osato, M., Nah, G. S. S., Yan, J., Chung, T. -H., Voon, D. C. -C., . . . Ng, S. -B. (2017). RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC. LEUKEMIA, 31(10), 2219-2227. doi:10.1038/leu.2017.40.
  • 5. Krishnan, V., & Ito, Y. (2017). Runx3 loss turns on the dark side of tgf-beta signaling. Oncoscience, 4(11-12), 156-157. doi:10.18632/oncoscience.382.